ArticlePediatric nephrology (Berlin, Germany)2021
A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- Rituximab in Pediatric Steroid-Resistant Nephrotic Syndrome: How Early is Early Enough?Kidney international reports · 2026Article
- Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.Kidney international reports · 2026Article
- Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.Kidney international reports · 2026Article
- Daratumumab for Treatment of Refractory Podocytopathy: A Case Report.Kidney medicine · 2026Article
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Article
- Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.Biomedicines · 2025Review
- Article
- Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome.Journal of clinical medicine · 2025Article
- Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up.Frontiers in immunology · 2025Article
- Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience.Frontiers in immunology · 2025Article
- Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.Kidney international reports · 2024Article
- Effects of immunosuppressive therapy on renal prognosis in primary membranous nephropathy.BMC nephrology · 2024Article
- Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases.Kidney international reports · 2024Article
- Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Application of CD38 monoclonal antibody in kidney disease.Frontiers in immunology · 2024Review
- Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.Frontiers in immunology · 2023Review
- The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature.European journal of pediatrics · 2022Review
- Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroid-sensitive nephrotic syndrome (SSNS) is, in most patients, a chronic disease with 80% experiencing at least one relapse after first flare. B cell depletion using rituximab is effective in preventing relapse in steroid-dependent (SDNS) patients but fails to maintain long-term remission following B cell recovery, possibly due to development of autoreactive long-lived plasma cells. We investigated sequential combination of antiCD20 antibody targeting all B cell subsets, and antiCD38 antibody with high plasma cell cytotoxicity in patients with uncontrolled SDNS after failure of one or several attempts at B cell depletion.
methodsFourteen patients with median disease duration 7.8 years received 1000 mg/1.73 m
resultsMedian age at treatment was 11.0 [IQR 10.4-14.4] years. B cell depletion was achieved in all patients, and B cell reconstitution occurred in all at median 9.5 months after obinutuzumab injection. After median follow-up 20.3 months (IQR 11.5-22.6), 5/14 patients relapsed including 4 within 100 days following B cell repletion. Relapse-free survival was 60% at 24 months from obinutuzumab infusion. Mild infusion reactions were reported in 3/14 patients during obinutuzumab and 4/14 during daratumumab infusions. Mild transient neutropenia (500-1000/mm
conclusionGlobal antiB cell strategy combining obinutuzumab and daratumumab induces prolonged peripheral B cell depletion and remission in children with difficult-to-treat SDNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.